Debby Morris appointed to Biote Board of Directors

Personalised hormone therapy company Biote Corp has announced the appointment of Debby Morris to Biote’s Board of Directors.

Biote trains practitioners how to identify and treat early indicators of hormone-related ageing conditions, providing affordable symptom relief for patients.

Morris has more than three decades of experience in directing financial operations and strategy to support high-growth companies.

She previously served as the executive vice president and chief financial officer of Apria, Inc. from March 2013 through October 2022.

Previous roles include Chief Financial Officer-Americas at Sitel Worldwide Corporation and partner of Tatum LLC from 2004 to 2010 and as a director from 2008 to 2010.

Morris also serves as a director for Alternative Logistics Technologies, Holdco, LLC (a.k.a EverDriven) and serves as the chair of the audit committee.

Biote CEO, Terry Weber, said:

“We are delighted to welcome Debby Morris to Biote.

“Debby is an accomplished executive whose deep financial and business expertise—spanning accounting and finance, SEC reporting, internal audit, data analytics, corporate development, and operations—will complement and strengthen our Board.

“We expect that Debby’s contributions and perspective will prove valuable as Biote continues to execute on our growth strategy.”

Debby Morris said:

“I am honoured to join the board of Biote at this time of growth and continued geographic expansion.

“I look forward to drawing on my financial and capital markets experience to advance Biote’s success as a new public company.”